Mounjaro and Vision Loss: What the FDA’s Latest Safety Update Says
Fibemed HealthcareShare
Recent headlines about Mounjaro and similar medicines have understandably raised questions about vision loss. Here is what regulators have said—and what patients should know.
On November 9, 2026, the U.S. Food and Drug Administration (FDA) announced that manufacturers must add information to GLP-1 medicine labeling about a “potential increased risk” of a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). The FDA’s list includes Mounjaro (tirzepatide), Zepbound, Ozempic and Wegovy. Tirzepatide acts on both GIP and GLP-1 receptors. Read the FDA safety communication.
This update does not mean that everyone taking these medicines will experience vision loss. The FDA describes a potential risk of a rare condition; it does not say that blindness is an inevitable effect of treatment.
What is NAION?
NAION is a condition involving reduced blood flow to the front part of the optic nerve. It typically causes sudden, painless changes in vision in one eye and can sometimes lead to permanent vision loss.
Possible symptoms include sudden blurring or loss of vision, blind spots or tunnel vision, distorted colors, or a hazy spot in the central field of vision.
What did the FDA’s review find?
The FDA reviewed data from 126 randomized clinical trials. In its pooled analysis, NAION occurred at a rate of 6.4 cases per 100,000 person-years among people taking GLP-1 medicines, compared with 3.8 cases per 100,000 person-years in comparison groups.
These are rare-event rates, not an individual prediction. The FDA described the finding as a potential increased risk; the figures do not establish that a medicine caused a particular person’s vision problem. Health conditions that may be relevant to NAION—including diabetes, high blood pressure, sleep apnea and smoking—can also complicate the assessment. See the FDA’s analysis and patient guidance.
Earlier in 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) said semaglutide treatment “may be very rarely associated” with NAION. Its estimate of up to 1 in 10,000 applies to semaglutide; it should not be presented as a specific risk estimate for Mounjaro or tirzepatide. Read the MHRA guidance.
What should patients do?
If you experience sudden vision loss or a rapid change in vision—especially in one eye—seek urgent medical advice. The FDA advises patients with these symptoms to “contact their health care professional right away.” A clinician can assess the symptoms and arrange an eye specialist review if needed.
Do not stop, start or change a prescribed medicine based only on a news headline. If you have concerns, discuss your personal health history, treatment benefits and possible risks with the clinician who prescribed it. If NAION is suspected or diagnosed, ask that clinician promptly whether your treatment plan should change.
A careful, individual discussion matters
The FDA’s announcement is a safety-labeling update about a potential risk. It is not a substitute for an individual medical assessment, and it does not mean that every patient should avoid or discontinue treatment. The right decision depends on a person’s medical history and should be made with a qualified healthcare professional.
Medical information notice: This article is for general educational purposes only. It is not a diagnosis or a substitute for medical advice, and it should not be used to make decisions about starting, stopping or changing medication. Fibemed Healthcare is an international health tourism agency; patients should consult their own prescribing clinician or ophthalmologist about medication and vision concerns.
Sources
U.S. FDA — GLP-1 receptor agonists and potential NAION risk, November 9, 2026:
https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
UK MHRA — Semaglutide and NAION, February 5, 2026:
https://www.gov.uk/drug-safety-update/semaglutide-wegovy-ozempic-and-rybelsus-risk-of-non-arteritic-anterior-ischemic-optic-neuropathy-naion
Sources checked November 11, 2026.